地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172469628
传真:17754422825
邮箱:sales@amyjet.com

Chemicell公司位于德国柏林,该公司主要进行创新的以纳米级磁珠为基础的生物分离、基因转染&检测系统开发和生产工作。开发的重点在于设计以客户为导向特别兼容了实验室自动化的即用型试剂盒。
chemicell develops and produces innovative bioseparation- gene transfection and detection systems based on magnetic nano- and microparticles. Focus of our product development is to design high quality customer-oriented "ready-to use" kits with special orientation towards the compatibility for labor automatisation. It is chemicell's policy to be open for cooperations with other companies or scientific institutes to maximize the chances and opportunities that evolve from the rapid development of biotechnological procedures and to distribute innovative new products.
主要产品包括:
Magnetofection™
Biomagnetic Separation
Magnetic Microparticles
Magnetic-Fluorescent Microparticles
Magnetic Nanoparticles
Magnetic-Fluorescent Nanoparticles
Microspheres-Non-Magnetic
Silica Microspheres-Non-Magnetic
Silica Fluorescent Microspheres-Non-Magnetic
Magnetic Separators
DNA / RNA Purification
PEG derivates
" data-original="http://antibodie.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Chemicell"> Chemicell
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://antibodie.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理rPeptide品牌全系列重组蛋白及多肽产品。
rPeptide公司提供高质量的肽、试剂、蛋白质、抗体等,专注于老年痴呆症和帕金森病的研究。rPeptide专有的平台载体技术能够在大肠杆菌中以可溶性肽/蛋白质的形式重组表达困难的肽/蛋白质。rPeptide还提供大量的β-淀粉样蛋白、taus、突触核蛋白、钙调素、定制产品等。
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
rPeptide产品详情请见艾美捷科技丁香通商城:
https://vicbio.biomart.cn/supply/c_282851.htm
<| Beta Amyloid 7E7 50ug and Beta Amyloid (1-40)NH4OH .25mg | BA-1101-1 | 50ug |
| Beta Amyloid 7E7 100ug and Beta Amyloid (1-40)NH4OH .5mg | BA-1101-2 | 100ug |
| Beta Amyloid 7E7 .5mg and Beta Amyloid (1-40)NH4OH .5mg | BA-1101-3 | 0.5mg |
| Beta Amyloid 7E7 1.0mg and Beta Amyloid (1-40)NH4OH 1.0mg | BA-1101-4 | 1.0mg |
| Beta Amyloid 7E7 50ug and Beta Amyloid (1-42)NH4OH .25mg | BA-1102-1 | 50ug |
| Beta Amyloid 7E7 100ug and Beta Amyloid (1-42)NH4OH .5mg | BA-1102-2 | 100ug |
| Beta Amyloid 7E7 .5mg and Beta Amyloid (1-42)NH4OH .5mg | BA-1102-3 | 0.5mg |
| Beta Amyloid 7E7 1.0mg and Beta Amyloid (1-42)NH4OH 1.0mg | BA-1102-4 | 1.0mg |
| Beta Amyloid 6C2 50ug and Beta Amyloid (1-40)NH4OH .25mg | BA-2201-1 | 50ug |
| Beta Amyloid 6C2 100ug and Beta Amyloid (1-40)NH4OH .5mg | BA-2201-2 | 100ug |
| Beta Amyloid 6C2 .5mg and Beta Amyloid (1-40)NH4OH .5mg | BA-2201-3 | 0.5mg |
| Beta Amyloid 6C2 1.0mg and Beta Amyloid (1-40)NH4OH 1.0mg | BA-2201-4 | 1.0mg |
| Beta Amyloid 6C2 50ug and Beta Amyloid (1-42)NH4OH .25mg | BA-2202-1 | 50ug |
| Beta-Amyloid 6C2, 100ug and Beta Amyloid (1-42) NH4OH 0.5mg | BA-2202-2 | 100ug |
| Beta Amyloid 6C2 .5mg and Beta Amyloid (1-42)NH4OH .5mg | BA-2202-3 | 0.5mg |
| Beta Amyloid 6C2 1.0mg and Beta Amyloid (1-42)NH4OH 1.0mg | BA-2202-4 | 1.0mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-02 | 1 x .25mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-1 | 1 x 0.5mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-2 | 1 x 1.0mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-02 | 1 x .25 mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-1 | 1 x 0.5 mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-2 | 1 x 1.0 mg |
| Beta-Amyloid (1-40), Mouse, Rat | A-1007-1 | 0.5 mg |
| Beta-Amyloid (1-40), Starter Kit | A-1150-1 | 5 x 0.5 mg |
| Beta-Amyloid (1-40), Starter Kit | A-1150-2 | 5 x 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, HCl | A-1156-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, HCl | A-1156-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, HFIP | A-1153-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, HFIP | A-1153-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, NaOH | A-1155-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, NaOH | A-1155-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, TFA | A-1001-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, TFA | A-1001-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-02 | 250 ug |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-2 | 1 mg |
| Beta-Amyloid (1-40, D23N) | A-1013-1 | 100 µg |
| Beta-Amyloid (1-40, D23N) | A-1013-2 | 1.0 mg |
| Beta-Amyloid (1-40, F4W) | A-1011-1 | 100 µg |
| Beta-Amyloid (1-11) | A-1051-1 | 1.0 mg |
| Beta-Amyloid (1-11) | A-1051-2 | 5.0 mg |
| Beta-Amyloid (1-16) | A-1052-1 | 1.0 mg |
| Beta-Amyloid (1-16) | A-1052-2 | 5.0 mg |
| Beta-Amyloid (1-28) | A-1053-1 | 0.5 mg |
| Beta-Amyloid (1-28) | A-1053-2 | 1.0 mg |
| Beta-Amyloid (1-38) | A-1078-1 | 0.5 mg |
| Beta-Amyloid (1-38) | A-1078-2 | 1.0 mg |
| Beta-Amyloid (11-22) | A-1055-1 | 1.0 mg |
| Beta-Amyloid (11-22) | A-1055-2 | 5.0 mg |
| Beta-Amyloid (11-40) | A-1061-2 | 1.0 mg |
| Beta-Amyloid (11-40), Mouse, Rat | A-1062-01 | 0.1 mg |
| Beta-Amyloid (11-40), Mouse, Rat | A-1062-1 | 0.5 mg |
| Beta-Amyloid (11-42) | A-1063-2 | 1.0 mg |
| Beta-Amyloid (12-28) | A-1056-1 | 0.5 mg |
| Beta-Amyloid (12-28) | A-1056-2 | 1.0 mg |
| Beta-Amyloid (17-40) | A-1057-1 | 0.5 mg |
| Beta-Amyloid (17-40) | A-1057-2 | 1.0 mg |
| Beta-Amyloid (17-42) | A-1058-1 | 0.5 mg |
| Beta-Amyloid (17-42) | A-1058-2 | 1.0 mg |
| Beta-Amyloid (22-35) | A-1059-1 | 1.0 mg |
| Beta-Amyloid (22-35) | A-1059-2 | 5.0 mg |
| Beta-Amyloid (25-35) | A-1060-1 | 1.0 mg |
| Beta-Amyloid (25-35) | A-1060-2 | 5.0 mg |
| 13C Beta-Amyloid (1-40), Uniformly labeled | A-1105-1 | 0.5 mg |
| 13C Beta-Amyloid (1-40), Uniformly labeled | A-1105-2 | 1.0 mg |
| 13C Beta-Amyloid (1-42), Uniformly labeled | A-1106-1 | 0.5 mg |
| 13C Beta-Amyloid (1-42), Uniformly labeled | A-1106-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-01 | 0.1 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-42), Uniformly labeled | A-1104-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-42), Uniformly labeled | A-1104-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-43), Uniformly labeled | A-1108-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-43), Uniformly labeled | A-1108-2 | 1.0 mg |
| 13C, Beta-Amyloid (1-43), Uniformly labeled | A-1109-1 | 0.5 mg |
| 13C, Beta-Amyloid (1-43), Uniformly labeled | A-1109-2 | 1.0 mg |
| 15N Beta-Amyloid (1-38), U. label | A-1147-1 | 0.1 mg |
| 15N Beta-Amyloid (1-38), U. label | A-1147-2 | 1.0 mg |
| 15N Beta-Amyloid (1-40), Rat, U. labeled | A-1131-1 | 0.5 mg |
| 15N Beta-Amyloid (1-40), Uniformly labeled | A-1101-1 | 0.1 mg |
| 15N Beta-Amyloid (1-40), Uniformly labeled | A-1101-2 | 1.0 mg |
| 15N Beta-Amyloid (1-42), Rat, U. labeled | A-1134-1 | 0.1 mg |
| 15N Beta-Amyloid (1-42), Rat, U. labeled | A-1134-2 | 1.0 mg |
| 15N Beta-Amyloid (1-42), Uniformly labeled | A-1102-1 | 0.1 mg |
| 15N Beta-Amyloid (1-42), Uniformly labeled | A-1102-2 | 1.0 mg |
| 15N Beta-Amyloid (1-43), Uniformly labeled | A-1107-1 | 1.0 mg |
| 15N Beta-Amyloid (1-46), U. label | A-1179-1 | 0.1 mg |
| 15N Beta-Amyloid (1-46), U. label | A-1179-2 | 0.5 mg |
| 15N Beta-Amyloid (11-40), Rat, U. label | A-1140-1 | 1.0 mg |
| 15N Beta-Amyloid (11-40), Uniformly labeled | A-1137-1 | 1.0 mg |
| 15N Beta-Amyloid (11-42), U. label | A-1120-2 | 1.0 mg |
| Biotin-Beta-Amyloid (1-40) | A-1111-01 | 0.1 mg |
| Biotin-Beta-Amyloid (1-40) | A-1111-2 | 1.0 mg |
| Biotin-Beta-Amyloid (1-42) | A-1117-1 | 0.5 mg |
| Biotin-LC-Beta-Amyloid (1-40) | A-1112-1 | 0.5 mg |
| Biotin-LC-Beta-Amyloid (1-40) | A-1112-2 | 1.0 mg |
| Biotin-LC-Beta-Amyloid (1-42) | A-1118-1 | 0.5 mg |
| Fluorescein-Beta-Amyloid (1-40) | A-1113-1 | 0.5 mg |
| Fluorescein-Beta-Amyloid (1-42) | A-1119-1 | 0.5 mg |
| Calmodulin, Porcine, Biotinylated | C-1002-1 | 100 µg |
| Calmodulin, Porcine, Fluorescein | C-1003-1 | 100 µg |
| Calmodulin, Porcine, Rhodamine | C-1004-1 | 100 µg |
| Calmodulin, Wheat (Triticum aestivum), Biotinylated | C-1008-1 | 50 µg |
| Calmodulin, Wheat (Triticum aestivum), Fluorescein | C-1009-1 | 50 µg |
| Calmodulin, Wheat (Triticum aestivum), Rhodamine | C-1010-1 | 50 µg |
| 15N Tau-441 (2N4R) Uniform Labeled | T-1101-1 | 50ug |
| 15N Tau-441 (2N4R) Uniform Labeled | T-1101-2 | 100ug |
| Tau Protein Ladder, of all 6 isoforms | T-1007-1 | 50 µl |
| Tau Protein Ladder, of all 6 isoforms | T-1007-2 | 100 µl |
| Tau Starter Kit | T-1170-1 | 50 µg |
| Tau Starter Kit | T-1170-2 | 100 µg |
| Tau-352, (0N3R) | T-1006-1 | 50 µg |
| Tau-352, (0N3R) | T-1006-2 | 100 µg |
| Tau-381, (1N3R) | T-1004-1 | 50 µg |
| Tau-381, (1N3R) | T-1004-2 | 100 µg |
| Tau-383, (0N4R) | T-1005-1 | 50 µg |
| Tau-383, (0N4R) | T-1005-2 | 100 µg |
| Tau-410, (2N3R) | T-1002-1 | 50 µg |
| Tau-410, (2N3R) | T-1002-2 | 100 µg |
| Tau-412, (1N4R) | T-1003-1 | 50 µg |
| Tau-412, (1N4R) | T-1003-2 | 100 µg |
| Tau-441, (2N4R) | T-1001-1 | 50 µg |
| Tau-441, (2N4R) | T-1001-2 | 100 µg |
| Tau-441, (2N4R), G272V mutant | T-1013-1 | 50 µg |
| Tau-441, (2N4R), P301L mutant | T-1014-1 | 50 µg |
| Tau-441, (2N4R), R406W mutant | T-1011-1 | 50 µg |
| Tau-441, (2N4R), V248L mutant | T-1015-1 | 50 µg |
| Tau-441, (2N4R), V337M mutant | T-1012-1 | 50 µg |
| Tubulin, Porcine | T-1201-1 | 1.0 mg |
| Latherin | L-1001-1 | 50ug |
| Latherin | L-1001-2 | 100ug |
| Latherin | L-1001-3 | 0.5mg |
| 15N, Alpha-Synuclein, Uniform Label | S-1004-1 | 0.5 mg |
| 15N, Alpha-Synuclein, Uniform Label | S-1004-2 | 1.0 mg |
| 15N, Beta-Synuclein, Uniform Label | S-1102-1 | .5mg |
| 15N, Beta-Synuclein, Uniform Label | S-1102-2 | 1.0mg |
| Alpha Synuclein Mouse | S-1010-1 | 0.5mg |
| Alpha Synuclein Mouse | S-1010-2 | 1.0mg |
| Alpha-Synuclein | S-1001-1 | 0.5 mg |
| Alpha-Synuclein | S-1001-2 | 1.0 mg |
| Alpha-Synuclein, 1-60 | S-1011-1 | 0.5 mg |
| Alpha-Synuclein, 1-95 | S-1012-1 | 0.5 mg |
| Alpha-Synuclein, 112 (NACP 112) | S-1016-1 | 0.5 mg |
| Alpha-Synuclein, 61-140 | S-1013-1 | 0.5 mg |
| Alpha-Synuclein, 96-140 | S-1014-1 | 0.5 mg |
| Alpha-Synuclein, A30P mutant | S-1005-1 | 0.5 mg |
| Alpha-Synuclein, A30P mutant | S-1005-2 | 1.0 mg |
| Alpha-Synuclein, A30P, A53T mutant | S-1006-1 | 0.5 mg |
| Alpha-Synuclein, A30P, A53T mutant | S-1006-2 | 1.0 mg |
| Alpha-Synuclein, A53T mutant | S-1002-1 | 0.5 mg |
| Alpha-Synuclein, A53T mutant | S-1002-2 | 1.0 mg |
| Alpha-Synuclein, Delta NAC | S-1015-1 | 0.5 mg |
| Alpha-Synuclein, E46K mutant | S-1008-1 | 0.5 mg |
| Alpha-Synuclein, E46K mutant | S-1008-2 | 1.0 mg |
| Beta-Synuclein | S-1003-1 | 0.5 mg |
| Beta-Synuclein | S-1003-2 | 1.0 mg |
| Gamma-Synuclein | S-1007-1 | 0.5 mg |
| Gamma-Synuclein | S-1007-2 | 1.0 mg |
| Gamma-Synuclein, Mouse | S-1009-1 | 0.5 mg |
| Gamma-Synuclein, Mouse | S-1009-2 | 1.0 mg |
| APP 669-711, HCl | AP-1156-1 | 0.5mg |
| APP 669-711, HCl | AP-1156-2 | 1.0mg |
| APP 669-711, HFIP | AP-1153-1 | 0.5mg |
| APP 669-711, HFIP | AP-1153-2 | 1.0mg |
| APP 669-711, N15 Uniformly Labelled | AP-1101-1 | 0.5mg |
| APP 669-711, N15 Uniformly Labelled | AP-1101-2 | 1.0mg |
| APP 669-711, NaOH | AP-1155-1 | 0.5mg |
| APP 669-711, NaOH | AP-1155-2 | 1.0mg |
| APP 669-711, NH4OH | AP-1157-1 | 0.5mg |
| APP 669-711, NH4OH | AP-1157-2 | 1.0mg |
| APP 669-711, TFA | AP-1001-1 | 0.5mg |
| APP 669-711, TFA | AP-1001-2 | 1.0mg |
| Apolipoprotein E, Human Plasma, VLDL | A-2001-1 | 50 µg |
| Alpha 1 Antichymotrypsin | A-2002-1 | 100 µg |
| Alpha 1 Antitrypsin | A-2003-1 | 1.0 mg |
| Alpha 2 Macroglobulin | A-2004-1 | 1.0 mg |
| Chymotrypsin | A-2005-1 | 100 µg |
| Haptoglobin | A-2006-1 | 1.0 mg |
| Myeloperoxidase | A-2007-1 | 100 µg |
| Plasmin | A-2008-1 | 1.0 mg |
| Plasminogen | A-2009-1 | 1.0 mg |
| Transferrin | A-2010-1 | 100 mg |
| Calmodulin, Porcine | C-1001-1 | 1 mg |
| Calmodulin, Wheat (Triticum aestivum) & Porcine | C-1006-1 | 200 µl |
| Calmodulin-SH, Wheat (Triticum aestivum) | C-1007-1 | 250 µg |
| Calmodulin-SH, Wheat (Triticum aestivum), Immobilized | C-1011-1 | 200 µl |
| Alpha Synuclein 10C3 Antibody | SA-3001-1 | 100ug |
| Alpha Synuclein 10C3 Antibody | SA-3001-2 | 1mg |
| Alpha Synuclein 10D2 Antibody | SA-3003-1 | 100ug |
| Alpha Synuclein 10D2 Antibody | SA-3003-2 | 1mg |
| Alpha Synuclein 5G4 Antibody | SA-3002-1 | 100ug |
| Alpha Synuclein 5G4 Antibody | SA-3002-2 | 1mg |
| Alpha Synuclein pAB 63 Antibody | SA-3004-1 | 100ul |
| Alpha Synuclein pAB 63 Antibody | SA-3004-2 | 1ml |
| Tau 3G3 | TA-3012-1 | 100ug |
| Tau 3G3 | TA-3012-2 | 1 mg |
| Tau 4C10 | TA-3011-1 | 100ug |
| Tau 4C10 | TA-3011-2 | 1mg |
| Tau 9D8 Antibody | TA-3010-1 | 100ug |
| Tau 9D8 Antibody | TA-3010-2 | 1mg |
| Tau total 12C2 | TA-3015-1 | 100ug |
| Tau total 12C2 | TA-3015-2 | 1mg |
| Tau total 18B5 | TA-3016-1 | 100ug |
| Tau total 18B5 | TA-3016-2 | 1 mg |
| Tau total 4B5 | TA-3013-1 | 100ug |
| Tau total 4B5 | TA-3013-2 | 1mg |
| Tau total 7E5 | TA-3017-1 | 100ug |
| Tau total 7E5 | TA-3017-2 | 1mg |
| Tau total 8F10 | TA-3014-1 | 100ug |
| Tau total 8F10 | TA-3014-2 | 1 mg |
| Tau total pAB 64 | TA-3020-1 | 100ul |
| Tau total pAB 64 | TA-3020-2 | 1 mg |
| Tau-10D3 Antibody | TA-3004-1 | 100ug |
| Tau-10D3 Antibody | TA-3004-2 | 1mg |
| Tau-10F8 Antibody | TA-3007-1 | 100ug |
| Tau-10F8 Antibody | TA-3007-2 | 1mg |
| Tau-1A6 Antibody | TA-2001-1 | 50ug |
| Tau-1A6 Antibody | TA-2001-2 | 100ug |
| Tau-1A6 Antibody | TA-2001-3 | 1.0mg |
| Tau-1A6 Antibody Kit | TA-1101-1 | 50ug |
| Tau-1A6 Antibody Kit | TA-1101-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2002 | TA-1102-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2002 | TA-1102-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2004 | TA-1104-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2004 | TA-1104-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2005 | TA-1105-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2005 | TA-1105-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2006 | TA-1106-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2006 | TA-1106-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2007 | TA-1107-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2007 | TA-1107-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2008 | TA-1108-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2008 | TA-1108-2 | 100ug |
| Tau-1E7 Antibody | TA-3001-1 | 100ug |
| Tau-1E7 Antibody | TA-3001-2 | 1mg |
| Tau-1F3 Antibody | TA-3005-1 | 100ug |
| Tau-1F3 Antibody | TA-3005-2 | 1mg |
| Tau-2B11 Antibody | TA-3008-1 | 100ug |
| Tau-2B11 Antibody | TA-3008-2 | 1mg |
| Tau-4G11 Antibody | TA-1001-1 | 50ug |
| Tau-4G11 Antibody | TA-1001-2 | 100ug |
| Tau-4G11 Antibody | TA-1001-3 | 1.0mg |
| Tau-4G11 Antibody Kit | TA-1111-1 | 50ug |
| Tau-4G11 Antibody Kit | TA-1111-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1003 | TA-1113-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1003 | TA-1113-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1004 | TA-1114-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1004 | TA-1114-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1005 | TA-1115-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1005 | TA-1115-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1006 | TA-1116-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1006 | TA-1116-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1007 | TA-1117-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1007 | TA-1117-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1008 | TA-1118-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1008 | TA-1118-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1009 | TA-1119-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1009 | TA-1119-2 | 100ug |
| Tau-5G7 Antibody | TA-3009-1 | 100ug |
| Tau-5G7 Antibody | TA-3009-2 | 1mg |
| Tau-8B11 Antibody | TA-3002-1 | 100ug |
| Tau-8B11 Antibody | TA-3002-2 | 1mg |
| Tau-8D2 Antibody | TA-3003-1 | 100ug |
| Tau-8D2 Antibody | TA-3003-2 | 1mg |
| Tau-9C8 Antibody | TA-3006-1 | 100ug |
| Tau-9C8 Antibody | TA-3006-2 | 1mg |
| Tau-E2+E3 9E11 | TA-3019-1 | 100ug |
| Tau-E2+E3 9E11 | TA-3019-2 | 1mg |
| Tau-E3 2B6 | TA-3018-1 | 100ug |
| Tau-E3 2B6 | TA-3018-2 | 1mg |
| AK-7 | N-3003-1 | 5 mg |
| AK-7 | N-3003-2 | 25 mg |
| ANA-12 | N-3031-1 | 5 mg |
| ANA-12 | N-3031-2 | 25 mg |
| Apomorphine HCI Hemihydrate | N-3027-1 | 100 mg |
| Apomorphine HCI Hemihydrate | N-3027-2 | 500 mg |
| Benztropine Mesylate | N-3012-1 | 1 gm |
| Bexarotene | N-3032-1 | 10 mg |
| Bexarotene | N-3032-2 | 50 mg |
| C-646 | N-3002-1 | 5 mg |
| C-646 | N-3002-2 | 25 mg |
| C16 | N-3030-1 | 5 mg |
| C16 | N-3030-2 | 25 mg |
| Candesartan | N-2049-1 | 20mg |
| Candesartan | N-2049-2 | 100mg |
| Celastrol | N-2187-1 | 10mg |
| Celastrol | N-2187-2 | 50mg |
| CNEE | N-1062-1 | 5mg |
| CNEE | N-1062-2 | 25mg |
| CTPB | N-3001-1 | 5 mg |
| CTPB | N-3001-2 | 25 mg |
| DAPT | N-3018-1 | 5 mg |
| DAPT | N-3018-2 | 25 mg |
| Deoxymannojirimycin HCl | N-2798-1 | 1mg |
| Deoxymannojirimycin HCl | N-2798-2 | 5mg |
| Diazoxide | N-3026-1 | 100 mg |
| Diazoxide | N-3026-2 | 500 mg |
| DMOG | MC-2371-1 | 10mg |
| DMOG | MC-2371-2 | 50mg |
| DU-14 | N-1187-1 | 5mg |
| DU-14 | N-1187-2 | 25mg |
| Edaravone | N-3034-1 | 1 gm |
| Edaravone | N-3034-2 | 5 gm |
| Entacapone | N-2025-1 | 10mg |
| Entacapone | N-2025-2 | 50mg |
| Epoxycholesterol | N-1330-1 | 1mg |
| Epoxycholesterol | N-1330-2 | 5mg |
| Ferrostatin-1 | N-1380-1 | 5mg |
| Ferrostatin-1 | N-1380-2 | 25mg |
| Fingolimod | N-3025-1 | 5 mg |
| Fingolimod | N-3025-2 | 25 mg |
| FK-506 | N-3024-1 | 20 mg |
| FK-506 | N-3024-2 | 100 mg |
| FPS-ZM1 | N-1635-1 | 5mg |
| FPS-ZM1 | N-1635-2 | 25mg |
| Gabapentin lactam | N-2535-1 | 50mg |
| Gabapentin lactam | N-2535-2 | 250mg |
| Imatinib Mesylate | N-3020-1 | 20 mg |
| Imatinib Mesylate | N-3020-2 | 100 mg |
| ISO-1 | N-3017-1 | 10 mg |
| ISO-1 | N-3017-2 | 50 mg |
| ISRIB | N-1539-1 | 5mg |
| ISRIB | N-1539-2 | 25mg |
| ISX9 | N-3010-1 | 5 mg |
| ISX9 | N-3010-2 | 25 mg |
| IU1 | N-1197-1 | 10mg |
| IU1 | N-1197-2 | 50mg |
| LM11A-31 2HCI | N-3005-1 | 5 mg |
| LM11A-31 2HCI | N-3005-2 | 25 mg |
| LM22A-4 | N-3006-1 | 10 mg |
| LM22A-4 | N-3006-2 | 50 mg |
| Minocyline HCI | N-3013-1 | 50 mg |
| Minocyline HCI | N-3013-2 | 250 mg |
| Mithramycin A | N-2085-1 | 1mg |
| Mithramycin A | N-2085-2 | 5mg |
| Mitoquinone | N-1363-1 | 5mg |
| Mitoquinone | N-1363-2 | 25mg |
| Montelukast Sodium | N-3028-1 | 50 mg |
| Montelukast Sodium | N-3028-2 | 250 mg |
| Mycophenolate mofetil | N-2086-1 | 50mg |
| Mycophenolate mofetil | N-2086-2 | 250mg |
| Neurodazine | N-3014-1 | 5 mg |
| Neurodazine | N-3014-2 | 25 mg |
| Neuropathiazol | N-3015-1 | 5 mg |
| Neuropathiazol | N-3015-2 | 25 mg |
| Noopept | N-2682-1 | 10mg |
| Noopept | N-2682-2 | 50mg |
| P7C3 | N-3004-1 | 5 mg |
| P7C3 | N-3004-2 | 25 mg |
| Phenylbutyrate Na | MC-1118-1 | 1gm |
| Phenylbutyrate Na | MC-1118-2 | 5gm |
| Pinacidil | N-2856-1 | 10mg |
| Pinacidil | N-2856-2 | 50mg |
| Prostratin | N-3011-1 | 1 mg |
| Prostratin | N-3011-2 | 5 mg |
| Rapamycin | N-3022-1 | 20 mg |
| Rapamycin | N-3022-2 | 100 mg |
| Resveratrol | N-3019-1 | 100 mg |
| Resveratrol | N-3019-2 | 500 mg |
| Roscovitine | N-1332-1 | 5mg |
| Roscovitine | N-1332-2 | 25mg |
| Salirasib | N-1461-1 | 5mg |
| Salirasib | N-1461-2 | 25mg |
| SB-225022 | N-3016-1 | 5 mg |
| SB-225022 | N-3016-2 | 25 mg |
| Tianeptine | N-3008-1 | 10 mg |
| Tianeptine | N-3008-2 | 50 mg |
| Tolcapone | N-3007-1 | 10 mg |
| Tolcapone | N-3007-2 | 50 mg |
| TRO 19622 | N-3029-1 | 5 mg |
| TRO 19622 | N-3029-2 | 25 mg |
| Vildagliptin | N-2887-1 | 20mg |
| Vildagliptin | N-2887-2 | 100mg |
| Vorinostat | N-3021-1 | 50 mg |
| Vorinostat | N-3021-2 | 250 mg |
| Zileuton | N-3023-1 | 10 mg |
| Zileuton | N-3023-2 | 50 mg |
| Zolmitriptan | N-3033-1 | 10 mg |
| Zolmitriptan | N-3033-2 | 50 mg |

艾美捷特约代理ATGen重组蛋白产品。
Atgen公司成立于2002年,主要从事重组蛋白和抗体的研发、生产。目前,Atgen为世界范围内的客户提供产品,包括神经蛋白,热休克蛋白,酶,泛素蛋白相关蛋白,病毒抗原,抗体和激素及相关抗体产品。
ATGen was founded in 2002 on the belief that ‘Health is the greatest wealth’. The company and its employees are committed to both improving quality of life and saving lives—whether by providing novel diagnostic tests, developing new therapies, or providing the research community with quality proteins and antibodies that are crucial for life science advancements. ATGen manufactures and distributes a large selection of recombinant proteins and monoclonal antibodies to over 200 research institutes in over 20 different countries.
Atgen的主要产品包括:
Neuroscience
Immunology
Glycobiology
Heat Shock Proteins
Cancer
Apoptosis
Signal Transduction
Transcription & Translation
Proteases & Inhibitors
Growth factors
" data-original="http://antibodie.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷特约代理ATGen重组蛋白产品"> 艾美捷特约代理ATGen重组蛋白产品
艾美捷科技特约代理ScienCell品牌。
ScienCell公司为研究界提供各种高质量的正常人类和动物细胞、细胞培养基和试剂、基因分析工具、细胞衍生的分子生物学产品、基于细胞的检测试剂盒和干细胞产品。
ScienCell公司产品线包括:
(1)原代细胞:采用ScienCell独有的方法从健康的人和动物组织中分离出来,在早期传代时进行冷冻保存,具有出色的细胞活力。
(2)细胞培养基:ScienCell的各种细胞培养基均为液体形式,包括特殊、经典和补充品种。每种产品均专为原代细胞的最佳营养和生长而设计。
(3)干细胞:干细胞是独特的细胞,具有在体内发育成各种特殊细胞类型的卓越能力,它们的特点是具有自我更新和分化成不同细胞谱系的能力。
(4)遗传学与基因组学:提供定制引物设计和试剂盒服务。
(5)分子生物学:产品:cDNA、基因组DNA、总RNA、MicroRNA、细胞裂解物和细胞沉淀。
(6)基于细胞的检测:ScienCell开发了多种基于细胞的检测检测试剂盒,包括新陈代谢、氧化应激和干细胞等许多领域,并提供酶活性、代谢物水平和细胞生长状态的定量结果。
(7)生长因子和蛋白质:ScienCell提供高质量生长因子、细胞因子和重组蛋白。
< " data-original="http://antibodie.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理ScienCell品牌"> 艾美捷科技特约代理ScienCell品牌
Trevigen致力于为研究人员提供高品质的试剂和试剂盒,用于细胞程序性死亡、DNA损伤和修复的研究。在过去的十年里,对于凋亡的研究越来越多,然而直到最近才开始将凋亡与DNA损伤联系在一起,并给予极大的关注。Trevigen能够为这一新兴领域提供高水平的产品和支持。而基于Trevigen在肿瘤研究产品核心业务的自然延伸,Trevigen开发出了一系列用于研究肿瘤细胞功能和行为的产品,包括血管生成、细胞侵袭、浸润和肿瘤形成等产品和试剂盒。所有Trevigen品牌的产品均基于最高质量标准生产,并被给予最强有力的技术支持。
Trevigen, Inc. is an innovative biotechnology company focused on the development of products and technology for cancer research and genetic toxicology, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 “Technology Corridor” in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, journal advertising, direct mail, and telemarketing, giving Trevigen worldwide recognition among those in the area of cancer research. Distributor appointments have been made in the Americas, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers in order to make us a part of the growing areas of government research and pharmaceutical research. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://antibodie.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Trevigen"> Trevigen
<Welligton实验室始建于1980年,致力于为客户提供高品质的标准物质,并始终站在环境科学的前沿,Wellington以矢志不渝的信念不断地推出新的合成物质,用于检测环境中不断出现的污染物。
Wellington Laboratories has been committed to providing high quality reference standards and exceptional customer service since its inception in 1980. An acute awareness of trends in the environmental community and a dedication to research and development has allowed us to synthesize a variety of emerging contaminants over the years. A few examples of The Science Behind Wellington are provided below for your review.
Wellington Laboratories的主要产品包括:
PCDD/PCDF Analytical Method Solutions
Individual PCDDs & PCDFs: Native and Mass-Labelled
Specialty Solution/Mixtures of PCDDs and PCDFs
PCB Analytical Method Solutions
Individual PCBs: Mass-Labelled
Specialty Solution/Mixtures of PCBs
Halogenated Flame Retardants & Related Compounds
Perfluorinated Compounds (PFCs)
Certified Reference Materials
Additional Products
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://antibodie.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Wellington Laboratories"> Wellington Laboratories
Molecular Innovations公司为全球的研究人员提供高质量的科研产品,包括纤溶酶原激活物抑制因子1,肾素,肾素原,玻连蛋白,纤维蛋白,纤维连接蛋白,血纤维蛋白溶酶原,血纤维蛋白溶酶,抗凝血酶,ELISA试剂盒,抗体和其他研究使用的试剂。
Molecular Innovations, founded in 1990, is a primary manufacturer of research antibodies, proteins and ELISA kits. We specialize in coagulation and thrombolysis reagents including PAI-1, tPA, urokinase, clotting factors, vitronectin, fibrinogen, fibronectin, clotting factors, prorenin/renin, albumin, and immunoglobulins. Our customers all over the world include pharmaceutical and biotechnology companies as well as major research institutions. We offer custom projects and bulk quotes. All products are manufactured under stringent quality control standards at our new state of the art facility in Novi, MI, USA.
Molecular innovations的主要产品包括:
Research Models
Molecular Biology
Purified Proteins
Elisa Kits
Monoclonal Antibodies
Polyclonal Antibodies
Inhibitors And Substrates
Chromatography Resins
Plasmas And Tissues
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

MetaSystems是一家雇员持股的德国公司,专门从事自动扫描和成像系统的开发,用于细胞遗传学,癌症遗传学、毒理学、病理学、法医科学和其他应用领域。在大力开发成像系统的同时,Mestasystem也逐步扩增其探针产品系列,如全染色体涂染试剂盒(XCP)、小鼠和大鼠多色mFISH探针(21XMouse和22XRat)、染色体臂特异性mFISH探针(XaCyte)等。早在2009年MetaSystems就曾引进新系列用于血液学研究的染色体特殊位点探针。
主要产品:
1. XL XCyting Locus-Specific Probe Kits位点特异性探针
血液学/肿瘤学荧光原位杂交探针 | ||
Chronic Myeloproliferative Disorders/慢性骨髓增生性疾病 | Myelodysplastic Syndromes/ | Burkitt Lymphoma/ |
CLL (Chronic Lymphocytic Leukemia)/慢性淋巴细胞白血病 | AML (Acute Myeloid Leukemia)/急性骨髓性白血病 | Diff. Large B-Cell Lymphoma/弥漫性大B淋巴瘤 |
ALL (Acute Lymphocytic Leukemia)/ | Multiple Myeloma/ | Follicular Lymphoma/ |
Mantle Cell Lymphoma/ | ||
2. XA XCyting AneuScore Probe Kits
3. XCP XCyting Chromosome Paints
XCyting Whole Chromosome Paints/全染色体涂染探针 | |
Human Chromosomes/人全染色体涂染探针 | Mouse and Rat Chromosomes/小鼠及大鼠染色体涂染探针 |
XCyting 染色体臂特异性探针 | |
4.XCE XCyting Centromere Enumeration Probes
5.XCyting Multicolor DNA Probe Kits
人类染色体多色FISH探针试剂盒 | ||
24XCyte mFISH Probe Kit | Arm-Specific mFISH Probe Kit/染色体臂特异性mFISH探针 | Centromeric mFISH Kit/着丝粒mFISH探针 |
小鼠和大鼠染色体多色FISH探针试剂盒 | ||
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://antibodie.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Metasystems"> Metasystems
艾美捷科技代理SeraCare对照及参比物质。
艾美捷科技有限公司,自2018年与SeraCare(现隶属于LGC Clinical Diagnostics)合作以来,长期为中国客户提供包括SeraSeq系列参比物质,领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质,可以用于任何研发阶段,以确保临床基因组学检测结果的准确性。
SeraCare参比物质涵盖的范围:
1)Next Generation Sequencing
2)Sanger Sequencing
3)Real-time PCR and digital PCR (dPCR)
4)Microarray
主要特点
1)Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, and RNA fusions
2)Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs
3)Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA in plasma, and FFPE
4)Manufactured in cGMP-compliant, ISO 13485-certified facilities
5)Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers
| 参比物质 | 货号 | 规格 |
| Seraseq® Whole Transcriptome RNA Seq Mix | 0710-2129 | 1 x 20 µl |
| Seraseq® Unmethylated ctDNA Mutation Mix | 0710-3088 | 1 x 25 µl |
| Seraseq® Tumor Mutation DNA Mix v2 AF 7 HC | 0710-0095 | 1 x 25 µl |
| Seraseq® Tumor Mutation DNA Mix v2 AF 10 HC | 0710-0094 | 1 x 25 µl |
| Seraseq® Tri-Level Tumor Mutation DNA Mix v2 HC | 0710-0097 | 1 x 25 µl |
| Seraseq® TNA (DNA/RNA) WT Mix | 0710-1580 | 2 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +6 copies | 0710-2867 | 1 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +3 copies | 0710-2866 | 1 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +12 copies | 0710-2868 | 1 x 20 µl |
| Seraseq® NTRK Fusion RNA Mix | 0710-1696 | 1 x 20 µl |
| Seraseq® Myeloid Mutation DNA Mix | 0710-0408 | 1 x 25 µl |
| Seraseq® Myeloid Fusion RNA Mix | 0710-0407 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix WT | 0710-2646 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF1% | 0710-2649 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF0.5% | 0710-2648 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF0.1% | 0710-2647 | 1 x 25 µl |
| Seraseq® MSI Reference Panel Mix AF5% | 0710-1675 | 2 x 15 µl |
| Seraseq® MSI Reference Panel Mix AF20% | 0710-1676 | 2 x 15 µl |
| Seraseq® Methylated ctDNA Mutation Mix | 0710-3089 | 1 x 25 µl |
| Seraseq® Lymphoma DNA Mutation Mix | 0710-2203 | 1 x 25 µl |
| Seraseq™ Lung & Brain CNV Mix, + 6 copies | 0710-0415 | 1 x 20 µl |
| Seraseq® Lung & Brain CNV Mix, + 3 copies | 0710-0414 | 1 x 20 µl |
| Seraseq® Lung & Brain CNV Mix, + 12 copies | 0710-0416 | 1 x 20 µl |
| Seraseq® HRD gDNA Negative Mix | 0710-2881 | 2 x 20 µl |
| Seraseq® HRD gDNA Low-Positive Mix | 0710-2880 | 2 x 20 µl |
| Seraseq® HRD gDNA High-Positive Mix | 0710-2879 | 2 x 20 µl |
| Seraseq® gDNA TMB Reference Panel Mix | 0710-2463 | 5 x 20 µl |
| Seraseq® gDNA TMB Mix Score 9 | 0710-1325 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 7 | 0710-1326 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 26 | 0710-1323 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 20 | 0710-1324 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 13 | 0710-1586 | 2 x 10 µl |
| Seraseq® gDNA MSI-High Mix | 0710-1670 | 1 x 20 µl |
| Seraseq® gDNA BRCA1/2 LGR Somatic Mutation Mix | 0730-0567 | 1 x 25 µl |
| Seraseq® gDNA BRCA1/2 LGR Inherited Mutation Mix | 0730-0568 | 1 x 25 µl |
| Seraseq® Fusion RNA Mix v4 | 0710-0497 | 1 x 25 µl |
| Seraseq® FFPE WT (DNA/RNA) Reference Material | 0710-0137 | 1 x 10 µm |
| Seraseq® FFPE TMB RM Score 9 | 0710-1308 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 7 | 0710-1310 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 26 | 0710-1307 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 20 | 0710-1309 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 13 | 0710-1618 | 2 x 10 um |
| Seraseq® FFPE Solid Tumor CNV Reference Materials | 0710-2865 | 1 x 10 µm |
| Seraseq® FFPE NTRK Fusion RNA Reference Material | 0710-1031 | 1 x 10 µm |
| Seraseq® FFPE MSI-High RM | 0710-2236 | 1 x 10 um |
| Seraseq® FFPE Lymphoma DNA Reference Material | 0710-2202 | 1 x 10 µm |
| Seraseq® FFPE HRD Negative RM | 0710-2644 | 1 x 10 µm |
| Seraseq® FFPE HRD Low-Positive RM | 0710-2645 | 1 x 10 µm |
| Seraseq® FFPE HRD High-Positive RM | 0710-2643 | 1 x 10 µm |
| Seraseq® FFPE Tumor Fusion RNA v4 Reference Material | 0710-0496 | 1 x 10 µm |
| Seraseq® FFPE BRCA1/2 LGR Reference Material | 0730-0564 | 1 x 10 µm |
| Seraseq® ctDNA Reference Material v2 WT | 0710-0208 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF2% | 0710-0203 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF1% | 0710-0204 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF0.5% | 0710-0205 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF0.125% | 0710-0207 | 1 x 5 mL |
| Seraseq® ctDNA Mutation Mix v2 WT | 0710-0144 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF2% | 0710-0139 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF1% | 0710-0140 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.5% | 0710-0141 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.25% | 0710-0142 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.125% | 0710-0143 | 1 x 25 µl |
| Seraseq® ctDNA MRD Panel Mix | 0710-2146 | 4 x 20 µl |
| Seraseq® ctDNA Complete™ Reference Material WT (0%) | 0710-0674 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF5% | 0710-0669 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF2.5% | 0710-0670 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF1% | 0710-0671 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF0.5% | 0710-0672 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF0.1% | 0710-0673 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Mutation Mix WT (0%) | 0710-0533 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF5% | 0710-0528 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF2.5% | 0710-0529 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF1% | 0710-0530 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF0.5% | 0710-0531 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF0.1% | 0710-0532 | 1 x 25 µl |
| Seraseq® Compromised FFPE WT (DNA/RNA) RM | 0710-1710 | 1 x 10 µm |
| Seraseq® Compromised FFPE Tumor DNA RM | 0710-1492 | 1 x 10 µm |
| Seraseq® Breast CNV Mix, + 6 copies | 0710-0412 | 1 x 20 µl |
| Seraseq® Breast CNV Mix, + 3 copies | 0710-0411 | 1 x 20 µl |
| Seraseq® Breast CNV Mix, + 12 copies | 0710-0413 | 1 x 20 µl |
| Seraseq® Blood TMB Mix Score 7 | 0710-2087 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 26 | 0710-2090 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 20 | 0710-2089 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 13 | 0710-2088 | 3 x 20 µl |
| Seraseq® Turner Syndrome (XO) Reference Material | 0720-0952 | 1 x 1 mL |
| Seraseq® Trisomy 21 Male-Matched Reference Material | 0720-0167 | 1 x 1 mL |
| Seraseq® Trisomy 21 Female-Matched Reference Material | 0720-0168 | 1 x 1 mL |
| Seraseq® Trisomy 18 Male-Matched Reference Material | 0720-0171 | 1 x 1 mL |
| Seraseq® Trisomy 18 Female-Matched Reference Material | 0720-0172 | 1 x 1 mL |
| Seraseq® Trisomy 13 Male-Matched Reference Material | 0720-0779 | 1 x 1 mL |
| Seraseq® Trisomy 13 Female-Matched Reference Material | 0720-0780 | 1 x 1 mL |
| Seraseq® Triple X Syndrome (XXX) Reference Material | 0720-1069 | 1 x 1 mL |
| Seraseq® PGT-A Trisomy 21 Reference Material | 0720-0775 | 1 x 10 µl |
| Seraseq® PGT-A Trisomy 18 Reference Material | 0720-0776 | 1 x 10 µl |
| Seraseq® PGT-A Trisomy 13 Reference Material | 0720-0777 | 1 x 10 µl |
| Seraseq® PGT-A Euploid Reference Material | 0720-0778 | 1 x 10 µl |
| Seraseq® Klinefelter Syndrome (XXY) Reference Material | 0720-0953 | 1 x 1 mL |
| Seraseq® Jacobs Syndrome (XYY) Reference Material | 0720-0954 | 1 x 1 mL |
| Seraseq® Euploid Male-Matched Reference Material | 0720-0169 | 1 x 1 mL |
| Seraseq® Euploid Female-Matched Reference Material | 0720-0170 | 1 x 1 mL |
| Seraseq® 22q11 Male-Matched Reference Material | 0720-0173 | 1 x 1 mL |
| Seraseq® 22q11 Female-Matched Reference Material | 0720-0174 | 1 x 1 mL |
| Seraseq® Inherited Cancer DNA Mix v1 | 0730-0003 | 1 x 200 µL |
| Seraseq® gDNA BRCA1/2 LGR Inherited Mutation Mix | 0730-0568 | 1 x 25 µL |
| Seraseq® FFPE BRCA1/2 LGR Reference Material | 0730-0564 | 1 x 10 µm |
| Seraseq® Cardiomyopathy Reference Material | 0740-0021 | 1 x 200 µL |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:18372041646
邮箱:sales@amyjet.com
0.3501